|
Makashova V.V., Omarova Zh.G., Ponezheva ZH.B., Ivashkova T.A., Gorelov A.V.
Chronic hepatitis C and its outcomes: liver cirrhosis, hepatocellular carcinoma
|
№1 / 2023
|
|
Saranskaya Ya.E., Kiseleva L.M., Sachek A.A.
Regression of liver fibrosis in patients with chronic hepatitis C after a cycle of therapy with direct-acting antivirals
|
№1 / 2023
|
|
Vorobyeva O.V., Lastochkin A.V., Gimaldinova N.E., Romanova L.P., Yusov A.A.
Lung and liver changes during covid-19 infection in the presence of liver cirrhosis
|
№4 / 2020
|
|
Grushko I.P., Romanova E.B., Tverdokhlebova T.I.
The role of endothelial dysfunction in the pathogenesis of chronic hepatitis C and methods of its correction
|
№2 / 2020
|
|
Khaertynova I.M., Sozinova Yu.M., Galeeva N.V., Gaifullina E.G., Urmancheeva Yu.R., Gataullin M.R.
Experience of treatment with direct-acting antiviral drugs in patients with cirrhosis at the outcome of chronic hepatitis
|
№2 / 2017
|
|
Nikitin I.G., Chulanov V.P., Andreeva K.V., Murashko M.M.
Topical aspects in the organization of medical care for patients with chronic viral hepatitis
|
№1 / 2016
|
|
Ignatova T.M.
Use of telaprevir in real clinical practice
|
№3 / 2014
|
|
Malova Е.S., Glazkova Е.Ya., Morozov V.G., Rybkina А.А., Morozov A.V., Safiullina N.Kh., Balmasova I.P.
Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C on the basis of routine laboratory indices
|
№1 / 2013
|
|
Znoiko O.O., Dudina K.R., Safiullina N.Kh., Karandashova I.V., Chulanov V.P.
Changes in the degree of hepatic fibrosis due to three-year entecavir therapy in a patient with chronic hepatitis B with an outcome to hepatic cirrhosis
|
№6 / 2012
|
|
Nagoyev B.S., Tadeyeva A.K.
The prooxidant and antioxidant systems in hepatic cirrhosis
|
№2 / 2012
|
Русский
